SEC Form 4 · accession 0001144204-15-038750
SYNAGEVA BIOPHARMA CORP · GEVA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Stephen R Biggar
Other
Period of report
Jun 22, 2015
Accepted (ET)
Jun 23, 2015 · 5:43 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000911326
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Jun 22, 2015 | D | 102 | — | D | 0 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Disposition of securities directly held by Stephen R. Biggar, an employee of Baker Bros. Advisors LP in connection with completion of the acquisition of Synageva Biopharma Corp. (the "Issuer") by Alexion Pharmaceuticals, Inc. pursuant to the Agreement and Plan of Reorganization (the "Merger Agreement") dated May 5, 2015, by and among Alexion Pharmaceuticals, Inc., the Issuer, Merger Sub Inc. and Galaxy Merger Sub LLC. Pursuant to the Merger Agreement the Issuer's common shares were exchanged for $115 in cash and 0.6581 share of Alexion Pharmaceuticals, Inc. common stock.
Remarks
Pursuant to the consummation of the merger pursuant to the Merger Agreement (as defined in footnote 1) on June 22, 2015 Stephen R. Biggar, an employee of Baker Bros. Advisors LP tendered his resignation as a director of Synageva Biopharma Corp.